Johns Hopkins Medicine: Hard To Lose' Mutations In Tumors May Predict Response To Immunotherapy
January 27, 2023
January 27, 2023
BALTIMORE, Maryland, Jan. 27 (TNSjou) -- Johns Hopkins Medicine issued the following news release:
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy. Now, investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall TMB, termed & . . .
Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient's response to immunotherapy. Now, investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall TMB, termed & . . .